{"id":13256,"date":"2020-12-23T00:00:00","date_gmt":"2020-12-23T00:00:00","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/new-39-minute-covid-test-available-on-randox-bosch-vivalytic-platform\/"},"modified":"2020-12-23T00:00:00","modified_gmt":"2020-12-23T00:00:00","slug":"new-39-minute-covid-test-available-on-randox-bosch-vivalytic-platform","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/new-39-minute-covid-test-available-on-randox-bosch-vivalytic-platform\/","title":{"rendered":"New 39-minute COVID test available on Randox-Bosch Vivalytic platform"},"content":{"rendered":"

A rapid new coronavirus test, which provides results for Covid-19 in just 39 minutes, is now available on the Vivalytic, a point-of-care platform brought to market by Randox Laboratories and Bosch.
\nThe test for detection of the SARS-CoV-2 pathogen is currently the fastest PCR test (the gold standard of test methods) worldwide, and is predestined for decentralized use in mobile test centres at service stations or in airports, so that people who take the test can obtain a reliable result while at the testing site.
\nThe CE-approved test is now available in Europe. The test has a sensitivity of 98% and a specificity of 100%.
\n\u201cThis new rapid test will be a game-changer in the coronavirus testing landscape by allowing patients to receive their results at the point of care faster than before,\u201d said Dr. Heather McMillan, Molecular R&D Manager at Randox Biosciences.
\nRandox and Bosch launched the first rapid test for the Vivalytic analyser at the end of March, after just six weeks\u2019 development.
\nAs a multiplex test, it simultaneously checks samples for the SARS-CoV-2 virus as well as nine other respiratory diseases in two and a half hours, whereas the new accelerated test is exclusively for SARS-CoV-2.
\nMarc Meier, president of Bosch Healthcare Solutions, cmmented: \u201cWith our different coronavirus tests and variable analysis strategies, we open up a range of testing scenarios with a Vivalytic device \u2013 from screening all the way to supporting differential diagnosis for similar symptoms.\u201d
\nDevelopment work for Covid-19 tests on the Vivalytic is ongoing: As of early October 2020, by pooling samples together it will be possible to simultaneously evaluate five samples in one test cartridge and at a comparable speed \u2013 a world first.
\nThis will increase available testing capacity by enabling fully automated processing of more than 160 samples a day using a Vivalytic device.
\nKey benefits<\/b>
The advantages of the rapid SARS-CoV-2 test on Vivalytic lie not only in speedy analysis, but also in ease of use. A sample is taken from the nose or throat using a swab, and placed in the test cartridge. Then the cartridge, which contains all the reagents required for the test, is inserted into the Vivalytic device for automated analysis.<\/p>\n